ScholarLens Back to search
2016•Transplantation and Cellular TherapyOpen access

Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT)

Amanda F. Cashen, Kendall Gosch, Theresa Fletcher, Connie S. Ceriotti, Armin Ghobadi, Ravi Vij, Keith E Stockerl-Goldstein, John F. DiPersio, Camille N. Abboud

Open full text 0 citations

Abstract

BEAM is widely used as the high dose chemotherapy given to patients with non-Hodgkin (NHL) or Hodgkin lymphoma (HL) who are undergoing ASCT. The standard lyophilized formulation of melphalan (Alkeran) has several limitations based on its marginal solubility and the requirement to reconstitute it in propylene glycol (PG), which itself is associated with toxicities. PG-free melphalan overcomes these limitations by using the solubilizing agent Captisol to improve the stability of the reconstituted melphalan.

Open-access reader

About this research paper

What this paper is about

BEAM is widely used as the high dose chemotherapy given to patients with non-Hodgkin (NHL) or Hodgkin lymphoma (HL) who are undergoing ASCT. The standard lyophilized formulation of melphalan (Alkeran) has several limitations based on its marginal solubility and the requirement to reconstitute it in propylene glycol (PG), which itself is associated with toxicities. PG-free melphalan overcomes these limitations by using the solubilizing agent Captisol to improve the stability of the reconstituted melphalan.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BEAM is widely used as the high dose chemotherapy given to patients with non-Hodgkin (NHL) or Hodgkin lymphoma (HL) who are undergoing ASCT. The standard lyophilized formulation of melphalan (Alkeran) has several limitations based on its marginal solubility and the requirement to reconstitute it in propylene glycol (PG), which itself is associated with toxicities. PG-free melphalan overcomes these limitations by using the solubilizing agent Captisol to improve the stability of the reconstituted melphalan.

Key concepts: Melphalan, Carmustine, Medicine, Etoposide, Chemotherapy, Cytarabine, Lymphoma, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT) — Research Paper | ScholarLens